All News

EULAR.Docs.APP

Day 2 Report from EULAR 2026

Jack Cush, MD

Day two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease.  Here are a few of my favorites from Day 2. 

Read Article
Lung.Pleural.inflamm.AI

RA-ILD: Screening risk and genetic susceptibility

Mrinalini Dey, MD

RA-ILD remains one of the most serious extra-articular manifestations of RA, contributing substantially to morbidity and mortality. Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development.

Read Article
change,future,lens,clarity

‘Strong’ treatment predictions in inflammatory myositis

Janet Pope, MD, MPH, FRCPC

Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).

Read Article
EULAR flags

Vasculitis Updates: Glucocorticoid use in AAV and GCA

2026 EULAR Press Release

Glucocorticoids are the cornerstone of initial vasculitis treatment, used to rapidly control inflammation and protect vital organs. EULAR has recommendations that cover glucocorticoid use in ANCA associated vasculitides (AAV) and large vessel vasculitis, including giant cell arteritis (GCA).1,2 But the evidence base continues to grow about their use – especially over the long term.

Read Article
RheumNow’s expanded coverage of the #EULAR2026 annual meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush RheumNow ( View Tweet)

One of the main changes in the 2025 update on the EULAR guidelines for imaging in SpA is that of MRI replacing CR as the initial imaging modality while CR & low dose CT of SIJs became alternative modalities in the absence of or if with CIs to MRI AbsPOS0682 @RheumNow #EULAR2026 https://t.co/bj2NWKnIGf

Links:

sheila RHEUMarampa ( View Tweet)
Treat-to-target in inflammatory arthritis recommended by every guideline. Followed in only 40% of SpA visits. The main reason was activity simply wasn’t documented using a validated index. You can’t target what you don’t measure. Abstr 0351 @ RheumNow #EULAR2026 #axSpA #PsA https://t.co/VAcoZfCXsR

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Getting #RA and IA diagnosed faster: UK RheumACaN program (integrated education + pathway redesign) ↑ clinician confidence 4.4 to 8.6/10. Referral within 3 days: 52% → 70%, with sustained improvement. Education that translates to real outcomes. @RheumNow #EULAR2026 POS0784 https://t.co/1Va9rkLBHM

Links:

Jiha Lee JihaRheum ( View Tweet)
Proud to present POS0784 at #EULAR2026. RheumACaN education + pathway redesign across primary and secondary care improved early inflammatory arthritis referrals within 3 working days from 52% to 70%, exceeding the national benchmark. 95% of clinicians changed their practice. https://t.co/W6VViVRndp

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
⏰ The question rheumatologists keep asking: Does early axSpA diagnosis reduce long-term spinal damage? Answer from the SCQM registry (n=376): Early diagnosis linked to 3.85 fewer mSASSS points long-term, esp. in HLA-B27+ males #POS0191 #EULAR2026 @RheumNow https://t.co/HM5kvqXMEh

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
📋 Do 2025 ASAS-SPARTAN criteria classify fewer real-world axSpA patients? Data from the RABBIT-SpA registry (n=2,236) confirms: 67% vs 73% with 2009 criteria Clinical arm rarely fulfilled #POS0190 #EULAR2026 @RheumNow https://t.co/HYie4w8c6r

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
DAY 1 & 2 Recap: EULAR 2026 Highlights https://t.co/uVMerChWN6

Links:

Dr. John Cush RheumNow ( View Tweet)

☂️What is an umbrella meta-analysis? It's a meta-analysis of meta-analyses ☔️ ⬇️This one showed the effect of diet supplementation on several RA outcomes Unfortunately, most studies have low levels of evidence #umbrella #rainy_London #EULAR2026 @rheumnow https://t.co/kYPchXEexn

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
🔍 Are 2025 ASAS-SPARTAN criteria valid in early axSpA? SPACE cohort (n=669): HIGH specificity (97.5%) but LOWER sensitivity (60%) vs 2009 criteria (83%) #OP0239 #EULAR2026 @RheumNow https://t.co/9wNbtcbP0l

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
A Field Whose Time Has Come: Launching the EULAR Study Group on Geriatric Rheumatology EULAR launches a Study Group on Geriatric Rheumatology — clinics increasingly serve older patients with multimorbidity, polypharmacy, frailty, cognitive and functional limits, yet research

Dr. John Cush RheumNow ( View Tweet)

Window of opportunity in stills disease is early. With IL1 / IL6 agents #sJIA and #AOSD are the same disease. - may need a standard new crieteria IL18 measuremnet should be encouraged. @RheumNow #EULAR2026 plenary https://t.co/EQbs9mDYjS

Links:

Bella Mehta bella_mehta ( View Tweet)
Transitioning from pediatrics to adult rheumatology for patients with autoinflammatory disease such as #AOSD should be done with administrative support and the right hand off. @RheumNow #EULAR2026 plenary talk https://t.co/N8qB7jrZfM

Links:

Bella Mehta bella_mehta ( View Tweet)
🔬 Can filgotinib improve axSpA? OLINGUITO (Phase 3 RCT, n=495): YES! ASAS40 39.5% vs 21% (r-axSpA) at week 16 #OP0234 #EULAR2026 @RheumNow https://t.co/0vj2KqSS1b

Links:

Nelly ZIADE 🍀 Nellziade ( View Tweet)
What defines MRI indicative of axSpA? This systematic lit review show adapting more stringent cutoffs in BME (>=4 SIJ quads, erosion >=3 quads, fat >=5 SIJ quads) & combined BME + structural lesions inc specificity. Time for updated definitions? AbsPOS0866 @RheumNow #EULAR2026 https://t.co/gkVbcOAiD3

Links:

sheila RHEUMarampa ( View Tweet)
@RheumNow WIN Nutrition session #EULAR2026 (4) 🌾 Gluten does NOT influence biologic response in RD, BELIEVE cohort, 197 pts. No need to go gluten-free unless celiac disease 🌱 Plants for Joints trial: plant-based diet + exercise → sustained DAS28&WOMAC improvement @ 2Y, RA/OA @RheumNow

Nelly ZIADE 🍀 Nellziade ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×